Metoprolol Succinate prices in the Asian market recorded a slight decline during the first half of May 2025, continuing the downward trend observed in April. Weak demand, elevated supply levels, and a subdued cost environment continued to define the pricing landscape across the region’s key pharmaceutical hubs.

Metoprolol Succinate prices in Asia dropped in 1st half of May 2025, extending the decline from April due to oversupply and lack of demand.

In China, Metoprolol Succinate prices fell due to declining industrial activity, deflationary input costs and low international demand due to trade uncertainties.

Indian Metoprolol Succinate prices dropped in April due to lower Chinese export prices, favorable currency and increased domestic production leading to excess supply.

Cautionary buying and inventory management in key Asian markets also contributed to the soft pricing for Metoprolol Succinate.

Metoprolol Succinate prices will rise mildly in 2H May as stocks deplete, demand picks up and regional manufacturing activity improves.

According to ChemAnalyst, Metoprolol Succinate prices in China fell further as manufacturing activity slowed in April. The official Purchasing Managers Index dropped to 49.0, indicating decline in industrial production and weaker external demand and trade uncertainty. Producer Price Index also decreased by 2.5% y-o-y, adding to the deflationary trend in raw material costs. This reduced the pricing power of pharma companies and forced them to discount heavily to clear inventory. Meanwhile, weak international demand, especially from US due to trade tensions, made Chinese exporters to lower prices to remain competitive in the Asian market.

In India, Metoprolol Succinate prices continued to decline through April and into early May. Indian manufacturers benefited from lower raw material import costs as Chinese exporters reduced prices. The appreciation of Indian rupee against US dollar further helped in reducing import costs. Despite a ten month high in Manufacturing Purchasing Managers Index, demand for Metoprolol Succinate was weak. Buyers in pharma and healthcare sectors were delaying procurement and managing existing inventory in a market where product was available in plenty and prices were already soft. This led to inventory buildup and kept pressure on suppliers to reduce prices to move the stock.

Across both China and India, market participants faced similar challenges marked by oversupply, restrained procurement, and weaker export activity. These pressures collectively maintained a soft pricing environment for Metoprolol Succinate in the first half of May.

According to market, Metoprolol Succinate price will increase slightly in the second half of May in Asia. This is supported by inventory tightening and demand pickup. As manufacturers start to produce and restocking gains momentum, the price will move up. With limited stock and manufacturing to rebound this month, Metoprolol Succinate will recover moderately in the coming weeks.